Your fact-checks will appear here
The efficacy of palbociclib in improving progression-free survival in patients with HR-positive, HER2-negative advanced/metastatic breast cancer.
Three —, and —sit firmly as the standard first-line systemic option for HR‑positive, HER2‑negative advanced/metastatic breast cancer when combined with endocrine therapy, with guideline bodies and ran...
, as tested in the program, is the only CDK4/6 inhibitor with consistent, statistically significant overall survival (OS) advantages reported across multiple phase III trials (MONALEESA‑2, ‑3, and ‑7)...